Activities
Minutes from the EMA-EUnetHTA December 2018 Meeting now available
The minutes from the EMA-EUnetHTA Meeting, hosted by the European Medicines Agency on 7th December 2018, are now available for access. This was the 16th
Open Call for Patient Input for a new Joint Assessment on a medicinal product for the prevention of vaso-occlusive crises in sickle cell disease (SCD) patients aged 16 years and over.
Patient group input requested for a new Joint Assessment on a medicinal product for the prevention of vaso-occlusive crises in sickle cell disease (SCD) patients
OTCA19 – ”Screening for osteoporosis in the general population” final assessment and related documentation is now available
EUnetHTA is pleased to announce that the final project plan, final assessment, comments from the external experts and authors’ answers, together with the final abstract
The public consultation of the draft methodological guideline “Practical considerations when critically assessing economic evaluations” is OPEN (deadline Oct. 11, 2019)
We are pleased to announce that, as of today, the draft methodological guideline “Practical considerations when critically assessing economic evaluations”, produced within WP6 B2, has
Open Call for Patient Input for a new Joint Assessment on a medicinal product for severe Gram-negative (bacterial) infections.
Patient group input requested for a new Joint Assessment on a medicinal product for severe Gram-negative (bacterial) infections. EUnetHTA deems patient involvement very important in
OTCA22 – “Clinical utility of Point-of-care Tests (POCT) D-Dimer and Troponin” project plan and comments from external experts are now available.
EUnetHTA is pleased to announce that the project plan and and comments from external experts for the Other Technologies Collaborative Assessment OTCA22 “Clinical utility of
Minutes from 2018 EUnetHTA-EFPIA Technical Meeting now available
The minutes from the EUnetHTA-EFPIA Technical Meeting, held on 11th December 2018 at the Haute Autorité de Santé in Paris, are now available for access.
PTJA11 – EUnetHTA is pleased to announce the start of the next Pharmaceutical Joint Assessment.
PTJA11 addresses ‘cefiderocol the for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options’, submitted by Shionogi BV.
The public consultation of the revision of the methodological guideline “Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness” is OPEN (deadline 27th September, 2019)
We are pleased to announce that, as of today, a revised version of the methodological guideline “Process of information retrieval for systematic reviews and health
PTJA07 Pharmaceutical Joint Assessment Now Available – ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response with, lost response to or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
This is the pharmaceutical Joint Assessment PTJA07 – on ustekinumab for the treatment of ulcerative colitis (UC). In September 2019, EMA approved the extension of
